Professional Experience Since joining the firm 32 years ago, Henry J. Renk has been engaged in all aspects of patent practice, including patent prosecution, counseling and patent infringement litigation. For the last 28 years, he has specialized in complex patent infringement litigation, principally in the pharmaceutical and chemical fields, in various district courts and before the International Trade Commission, including appeals to the United States Court of Appeals for the Federal Circuit. Mr. Renk has appeared as lead trial counsel for AstraZeneca, Bausch & Lomb, Merck, Alcatel, S.C. Johnson, Warner-Lambert Company and Monsanto Company in district court patent litigation, and for Union Carbide Corporation in a state court trade secret case. Mr. Renk also has been trial counsel in patent litigation for those and other clients, including Pharmacia, Novartis, Takeda Chemical Industries, SmithKlineBeecham, The NutraSweet Company, DuPont, IBM and Hoechst Celanese. Mr. Renk was formerly an adjunct Professor of Law at Pace University School of Law in White Plains, New York, where he taught Patent Law. Awards and Recognition Mr. Renk was selected as a top intellectual property law practitioner in every edition since 2003 of the Best Lawyers in America. He was also listed as a Top New York City Intellectual Property Litigator in the 2006-2011 issues of Super Lawyers: New York Metro Edition. Mr. Renk was listed in IAM Life Sciences 250- The World's Leading Life Sciences Patent Litigator 2010. He is listed as a leading lawyer in Legal 500 2010 for patent litigation: life sciences/chemical. Mr. Renk was also recognized in IAM 250: The World's Leading Patent Litigators 2011. For information on the selection processes, see: Best Lawyers Super Lawyers IAM Life Sciences 250 Legal 500 IAM 250 Professional Activities American Bar Association; New York Bar Association; Federal Circuit Bar Association; American and New York Intellectual Property Law Associations Decisions Representative Cases In re Rosuvastatin Calcium Patent Litigation
D. Del. 2010 AstraZeneca Pharmaceuticals LP and AstraZeneca UK Ltd., v. Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd and Sandoz, Inc.
Fed. Cir. 2009 AstraZeneca Pharmaceutical LP et al. v. Teva Pharmaceuticals USA, Inc, et al.
D.N.J. 2008 AstraZeneca Pharmaceuticals LP, et al. v. Teva Pharmaceuticals USA, Inc., et al.
D.N.J. 2007 University of Rochester v. G.D. Searle and Co., Inc., Pfizer Inc., Monsanto Co., and Pharmacia Corp.
Fed. Cir. 2004 University of Rochester v. G.D. Searle & Co., Inc., Pfizer Inc., Monsanto Co., and Pharmacia Corp.
W.D.N.Y. 2003 FTAP Holdings, Inc. et.al. V. OWL Pharmaceuticals LLC et.al.
N.D. Ohio 2002 Datapoint Corporation v. Standard Microsystems
Fed. Cir. 2002 Publications/Events Events Bio-Similars: The New Litigation Landscape
IPO Webcast
Partner Henry J. Renk spoke at IPO's Biologics webcast
April 22, 2010 ABA Intellectual Property Law Conference
American Bar Association
April 10, 2008 Best Practices for Litigating Polymorph and Pharmaceutical Patent Cases
3rd Annual Polymorphism & Crystallization Conference
November 15-17, 2004 Best Practices in Pharmaceutical Patent Litigation
Polymorphism & Crystallization Forum 2004: Science, Technology & Intellectual Property
April 26, 2004 Use of Prior Statements, Depositions and Corollary Proceedings: Searing Impeachment and Effective Rehabilitation
2003 AIPLA Spring Meeting
May 15, 2003 |